Repeat treatment for recurrent hepatocellular carcinoma: is it validated?

Area of Science:

• Hepatology
• Oncology
• Surgical Gastroenterology

Background:

• Hepatocellular carcinoma (HCC) frequently recurs after initial treatment.
• Locoregional treatments are often employed for recurrent HCC, especially when liver function is preserved.

Purpose of the Study:

• To evaluate the impact of repeated locoregional treatments on patient prognosis following hepatic resection for HCC.
• To identify predictors of survival after initial recurrence of HCC.

Main Methods:

• Retrospective review of 134 patients with HCC recurrence after hepatic resection.
• Analysis of recurrence patterns and treatment types.
• Univariate and multivariate analyses to determine prognostic factors.

Main Results:

• The median number of treatments post-recurrence was 3; transarterial chemoembolization was most common.
• The number of treatments, not the type, correlated with prognosis.
• Independent predictors of poor survival included impaired liver function (>20% indocyanine green retention), large primary tumor (>5 cm), short recurrence-free interval (<1 year), large recurrent tumor (>3 cm), and extrahepatic recurrence.

Conclusions:

• Prognosis for recurrent HCC is poor with large tumors or compromised liver function.
• Repeated locoregional treatment can improve patient outcomes, particularly in cases with smaller tumors, longer recurrence-free intervals, and absence of extrahepatic metastases.